問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


China Medical University Hospital (在職)

Digestive System Department

Division of General Internal Medicine

China Medical University Hospital-Taipei (在職)

Digestive System Department

更新時間：2023-09-19

馮俊龍Feng, Chun-Lung
  • Principal Investigator
  • Clinical Trial Experience (year) 12 years 9 個月

  • d6604@mail.cmuh.org.tw

Recruiting Trial

30Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

馮俊龍

List

44Cases

2022-11-30 - 2028-12-31

Phase II

Active
A Phase 2b Randomized, Double-blind, Active-and Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Induction and Maintenance Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease

  • Condition/Disease

    Crohn's Disease

  • Test Drug

    GuselkumabGolimumabJNJ-78934804

Participate Sites
4Sites

Not yet recruiting4Sites

2021-07-31 - 2024-12-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2025-07-01 - 2029-03-07

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2018-04-01 - 2024-07-16

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2018-04-01 - 2024-12-10

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2025-02-01 - 2033-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2024-11-20 - 2032-04-20

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2025-06-01 - 2028-11-15

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2025-06-01 - 2028-12-15

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2015-09-15 - 2019-09-30

Phase III

Completed
A Multicenter, Randomized, Open-label Study in Patients with esophageal Cancer refractory or intolerant to Combination Therapy with Fluoropyrimidine and Platinum-based Drugs

  • Condition/Disease

    Esophageal cancer

  • Test Drug

    ONO-4538 (Nivolumab)

Participate Sites
13Sites

Terminated11Sites

林振源
China Medical University Hospital-Taipei

未分科

顏厥全
Taipei Veterans General Hospital

Division of Hematology & Oncology

1 2 3 4 5
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB